The Therapies Scientific Committee (TSC) is establishing a Task Force on Drug Repurposing Guidebook to help developers (of all kinds) navigating the rare disease landscape and identifying specific tools and […]
Read MoreThe Therapies Scientific Committee (TSC) is establishing a Task Force on Drug Repurposing Guidebook to help developers (of all kinds) navigating the rare disease landscape and identifying specific tools and […]
Read MoreIRDiRC is pleased to announce the election of Dr David Pearce, President of Innovation, Research & World Clinics, Sanford Health (USA), as the next Chair of the IRDiRC Consortium Assembly. Dr Pearce […]
Read MoreIRDiRC is pleased to announce the election of Dr David Pearce, President of Innovation, Research & World Clinics, Sanford Health (USA), as the next Chair of the IRDiRC Consortium Assembly. Dr Pearce […]
Read MoreWe are proud to announce the publication of a commentary on 10 years of progress and challenges of IRDiRC in the prestigious journal Nature Reviews Drug Discovery. The article summarizes […]
Read MoreWe are proud to announce the publication of a commentary on 10 years of progress and challenges of IRDiRC in the prestigious journal Nature Reviews Drug Discovery. The article summarizes […]
Read MoreThe Therapies Scientific Committee (TSC) is establishing a Task Force to characterize specific commonalities amongst a large group of “disregarded” rare diseases, with the potential secondary aims to identify removable roadblocks that […]
Read MoreThe Therapies Scientific Committee (TSC) is establishing a Task Force to characterize specific commonalities amongst a large group of “disregarded” rare diseases, with the potential secondary aims to identify removable roadblocks that […]
Read MoreThe International Rare Diseases Research Consortium (IRDiRC) has published the results of its COVID-19 survey in the Rare Disease and Orphan Drugs Journal. The ambitious goals set by IRDiRC by 2027 […]
Read MoreThe International Rare Diseases Research Consortium (IRDiRC) has published the results of its COVID-19 survey in the Rare Disease and Orphan Drugs Journal.
Read More